Cargando…

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen’s Hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Kazuhito, Yoshimura, Yukihiro, Miyata, Nobuyuki, Sasaki, Hiroaki, Shiba, Aya, Aga, Masaharu, Hamakawa, Yusuke, Taniguchi, Yuri, Misumi, Yuki, Agemi, Yoko, Shimokawa, Tsuneo, Okamoto, Hiroaki, Tachikawa, Natsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963397/
https://www.ncbi.nlm.nih.gov/pubmed/35351942
http://dx.doi.org/10.1038/s41598-022-09170-4
_version_ 1784677981445160960
author Miyazaki, Kazuhito
Yoshimura, Yukihiro
Miyata, Nobuyuki
Sasaki, Hiroaki
Shiba, Aya
Aga, Masaharu
Hamakawa, Yusuke
Taniguchi, Yuri
Misumi, Yuki
Agemi, Yoko
Shimokawa, Tsuneo
Okamoto, Hiroaki
Tachikawa, Natsuo
author_facet Miyazaki, Kazuhito
Yoshimura, Yukihiro
Miyata, Nobuyuki
Sasaki, Hiroaki
Shiba, Aya
Aga, Masaharu
Hamakawa, Yusuke
Taniguchi, Yuri
Misumi, Yuki
Agemi, Yoko
Shimokawa, Tsuneo
Okamoto, Hiroaki
Tachikawa, Natsuo
author_sort Miyazaki, Kazuhito
collection PubMed
description Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen’s Hospital, Kanagawa, Japan. Patients with COVID-19 pneumonia treated with remdesivir were included. The onset of acute pancreatitis and increased pancreatic enzyme levels and clinical, laboratory, treatment, and outcome data were collected and analyzed. A total of 201 patients were included. Among the 201 patients treated with remdesivir, 177 recovered from COVID-19. Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in 23 of the 201 patients. The potential etiopathogenetic effects of remdesivir on increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis were ascertained by reviewing the characteristics of patients hospitalized for COVID-19 who did not receive remdesivir treatment. Only 3 of 159 patients had increased pancreatic enzyme levels of grade 3 or higher during the treatment course. Multivariate analysis indicated remdesivir administration and severe COVID-19 infection by National Institute of Health standards as independent risk factors. Acute pancreatitis and severe increases in pancreatic enzyme levels were observed among patients with COVID-19 treated with remdesivir.
format Online
Article
Text
id pubmed-8963397
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89633972022-03-30 Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study Miyazaki, Kazuhito Yoshimura, Yukihiro Miyata, Nobuyuki Sasaki, Hiroaki Shiba, Aya Aga, Masaharu Hamakawa, Yusuke Taniguchi, Yuri Misumi, Yuki Agemi, Yoko Shimokawa, Tsuneo Okamoto, Hiroaki Tachikawa, Natsuo Sci Rep Article Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen’s Hospital, Kanagawa, Japan. Patients with COVID-19 pneumonia treated with remdesivir were included. The onset of acute pancreatitis and increased pancreatic enzyme levels and clinical, laboratory, treatment, and outcome data were collected and analyzed. A total of 201 patients were included. Among the 201 patients treated with remdesivir, 177 recovered from COVID-19. Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in 23 of the 201 patients. The potential etiopathogenetic effects of remdesivir on increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis were ascertained by reviewing the characteristics of patients hospitalized for COVID-19 who did not receive remdesivir treatment. Only 3 of 159 patients had increased pancreatic enzyme levels of grade 3 or higher during the treatment course. Multivariate analysis indicated remdesivir administration and severe COVID-19 infection by National Institute of Health standards as independent risk factors. Acute pancreatitis and severe increases in pancreatic enzyme levels were observed among patients with COVID-19 treated with remdesivir. Nature Publishing Group UK 2022-03-29 /pmc/articles/PMC8963397/ /pubmed/35351942 http://dx.doi.org/10.1038/s41598-022-09170-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Miyazaki, Kazuhito
Yoshimura, Yukihiro
Miyata, Nobuyuki
Sasaki, Hiroaki
Shiba, Aya
Aga, Masaharu
Hamakawa, Yusuke
Taniguchi, Yuri
Misumi, Yuki
Agemi, Yoko
Shimokawa, Tsuneo
Okamoto, Hiroaki
Tachikawa, Natsuo
Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
title Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
title_full Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
title_fullStr Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
title_full_unstemmed Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
title_short Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
title_sort acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in covid-19 patients: an observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963397/
https://www.ncbi.nlm.nih.gov/pubmed/35351942
http://dx.doi.org/10.1038/s41598-022-09170-4
work_keys_str_mv AT miyazakikazuhito acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT yoshimurayukihiro acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT miyatanobuyuki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT sasakihiroaki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT shibaaya acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT agamasaharu acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT hamakawayusuke acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT taniguchiyuri acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT misumiyuki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT agemiyoko acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT shimokawatsuneo acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT okamotohiroaki acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy
AT tachikawanatsuo acutepancreatitisorsevereincreaseinpancreaticenzymelevelsfollowingremdesiviradministrationincovid19patientsanobservationalstudy